VITAMIN A (200,000 IU) AND VITAMIN E (40 IU) ORAL LIQUID PREPARATION CAPSULE

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Kupi sada

Svojstava lijeka Svojstava lijeka (SPC)
08-04-2016

Aktivni sastojci:

VITAMIN A (RETINYL PALMITATE); VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE)

Dostupno od:

NUTRICORP INTERNATIONAL

ATC koda:

A11JA

INN (International ime):

COMBINATIONS OF VITAMINS

Doziranje:

200000UNIT; 40UNIT

Farmaceutski oblik:

CAPSULE

Sastav:

VITAMIN A (RETINYL PALMITATE) 200000UNIT; VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE) 40UNIT

Administracija rute:

ORAL

Jedinice u paketu:

500

Tip recepta:

Prescription

Područje terapije:

VITAMIN A

Proizvod sažetak:

Active ingredient group (AIG) number: 0225696007; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2016-04-06

Svojstava lijeka

                                _ _
_Page 1 of 37_
PRODUCT MONOGRAPH
PR
VITAMIN A (200,000 IU) AND VITAMIN E (40 IU) ORAL LIQUID PREPARATION
VITAMIN A AND VITAMIN E SOFTGEL CAPSULES
200,000 IU Vitamin A (all-trans-retinyl palmitate) and 40 IU Vitamin E
(all-rac-alpha-
tocopheryl acetate)
One IU of Vitamin A is equivalent to the activity of 0.3 mcg of
all-trans-retinol
ATC code: Vitamins – A11
Nutricorp International
4025 Rhodes Drive
Windsor, Ontario
N8W 5B5
Date of Preparation:
April 5, 2016
Submission Control No: 167924
_ _
_ _
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................9
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
.......................................................
                                
                                Pročitajte cijeli dokument
                                
                            

Dokumenti na drugim jezicima

Svojstava lijeka Svojstava lijeka francuski 22-02-2017

Upozorenja za pretraživanje vezana za ovaj proizvod